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Abstract
PURPOSE: Obesity costs the U.S. roughly $147 billion in health care spending annually. There
has been a call for healthcare providers to initiate all possible weight loss interventions. One
treatment strategy not used to its fullest potential is that of prescribing antiobesity medications.
The purpose of this project was to examine and evaluate the effectiveness of three common
weight loss medications used in the treatment of obesity, including discussion and
recommendations.
METHODS: This project was a single-center retrospective study comparing three different
groups of patients seen at a rural weight loss clinic. The sample consisted of 84 patients seen
between September 2014 to September 2017. Three groups taking Adipex, Adipex + Contrave,
and Apidex + Saxenda were evaluated for effectiveness on weight loss, BMI, and waist
circumference. Compliance to medications, diet, and exercise were evaluated.
RESULTS: Each medication group proved to be effective in treating obesity. On average,
patients taking Adipex had 7.2% weight loss, Adipex + Contrave had 7.2% weight loss, and
Adipex + Saxenda averaged 9.1% weight loss. Compliance to diet and exercise was a
determinant for weight loss success. Those that did not comply to the medication regimen or a
diet and exercise plan did not decrease obesity measures.
CONCLUSION: Pharmacotherapy is an adjunctive therapy to diet and exercise. No differences
in the effectiveness of medication between groups was found; however, each medication was
statistically proven to be effective in obesity reduction. Adipex, while proving just as effective
as combination therapy, is the most affordable and when applicable should be considered along
with diet and exercise for those seeking weight loss.
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A Retrospective Comparative Analysis on the Effectiveness of Pharmacologic Weight Loss
Introduction
In a recent survey, Americans ranked obesity as the top health concern in the country
(State of Obesity, 2017). As obesity-related health issues continue to escalate, Americans seek
to reverse the trend by taking an interest in personal health and wellness by reaching for the “all
natural” or “organic” labels, hitting the gym, and fad dieting (Walsh, 2015). Perhaps this trend is
why 502 billion dollars are spent by consumers on prevention and wellness products (e.g.
vitamins, nutritional supplements, over the counter weight loss supplements, and fortified foods)
(Accenture, 2014). Health and wellness has been called “the next trillion-dollar marketplace”
and projected to grow 50% over the next five years (Accenture, 2014; Cloos et al., 2012). There
is a growing use of anti-obesity medications to help those who simply are not successful in
losing weight. The purpose of this project was to provide a retrospective analysis comparing the
effectiveness of three weight loss medications on weight, body mass index (BMI), and waist
circumference used in one weight loss clinic.
Background & Scope
Global
According to the World Health Organization (WHO) (2018), an estimated 2.8 million
people die each year secondary to being overweight or obese. The prevalence of overweight and
obesity is highest in North America (62% overweight, 26% obese) and lowest in South East Asia
(14% overweight, 3% obese) (WHO, 2018). Between 1980 and 2014, obesity rates more than
doubled worldwide (Manchi & de Melo, 2017). As of 2014, the WHO reported more than 1.9
billion adults over age 18 were overweight (38% men, 40% women); of those, over 600 million
were obese (11% men, 15% women) (2016).
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National
With an estimated 150 billion dollars spent on obesity related health care annually, and
billions more in production loss, obesity is now considered the most prevalent chronic disease in
the United States (Kim & Basu, 2016; Winterfield & Cauchi, 2014). As of 2011, a projected
cost of over 11 billion dollars was spent on medical costs for obese adults in the U.S. (The State
of Obesity, 2015). Obesity rates exceeded 35% in five states (West Virginia, Mississippi,
Alabama, Arkansas, and Louisiana); nationally, nearly 8% of adults fall into the extremely obese
(BMI >40) category (State of Obesity, 2017). Interestingly, in 1985, no state had an adult
obesity rate exceeding 15% and in 2006, only Mississippi was above 30% (State of Obesity,
2017).
In Table 1, gender demographics for obesity are outlined (see Table 1). Statistically
significant differences were seen in obesity rates and ethnicity. The highest prevalence is noted
in the Black community followed by Hispanics and then Caucasians. Level of education and
income have been recognized as factors in the prevalence of obesity. Of those who did not
graduate high school, 33% were found to be obese compared to 22% of those who went to
college or technical college (State of Obesity, 2017). More than 33% of adults who earned less
than 15,000 dollars per year were obese compared to 24.5% who earned at least 50,000 dollars
per year (State of Obesity, 2017).
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Table 1.
National Obesity Rates, 2017
National Obesity Rates, 2017
Men & Women

Men

Women

Overall

38%

35%

40.4%

Blacks

57.2%

38%

38%

Latinas

46.9%

37.9%

Unknown

Whites

38.2%

34.7%

34.7%

Asians

12.4%

Unknown

Unknown

Note: data from the State of Obesity Annual Reports. Retrieved from http://www.stateofobesity.org/obesity-ratestrends-overview/ (2017).

The 2017 State of Obesity Annual Report recorded a decline in obesity rates for 2016 in
four states (Minnesota, Montana, New York, & Ohio). This is the first time a reduction has been
seen since data collection; yet, obesity remains one of America’s most prevalent health
problems. The etiology centers on the American lifestyle when one evaluates reported current
diet and exercise patterns. Less than half of Americans meet U.S. aerobic guidelines, greater
than 70% do not meet the recommended daily servings of fruits or vegetables, approximately
49% of adults drink a sugar-sweetened beverage per day, and most exceed recommended levels
of solid fats, added sugar, and sodium (State of Obesity, 2017).
Local. Kentucky is currently ranked seventh for highest rate of obesity in the country
with a rate of 34.2% (State of Obesity, 2017). Kentuckians living in rural areas, particularly the
Appalachian region, have a higher prevalence of being overweight or obese, and have more
obesity-related health conditions than those living in other state rural regions (Schoenberg et al,
2013). Alarmingly, between 2008-2010, two in three adult Kentuckians were overweight
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(67.1%) and three in ten (31.5%) were obese (Walsh et al., 2012). Seven in ten (70.1%) of
Appalachian adults were overweight and one in three (34.6%) were obese (Walsh et al., 2012).
According to the State of Obesity Annual Reports (2012), those living in the Appalachian region
have experienced an increase in the prevalence of obesity in the past eight years.
The Appalachian communities are socioeconomically impoverished and have decreased
access to health care. There is a higher prevalence of smoking, poor eating habits, inactivity, and
mental health disorders (Schoenberg, Huang, Seshadri, & Tucker, 2015). According to the most
recent data, 28.4% of those living in the Appalachian region are physically inactive (Marshall &
Alcalde, 2017). As of 2011, 17% of Kentuckians forego medical care due to cost and 16% have
no personal health care provider (Walsh et al., 2012).
Affordability of high quality food, insufficient transportation, and geographic locations
were described by Appalachian residents as some of the greatest barriers for battling obesity
(Schoenberg et al., 2015). One resident from Harlan county stated, “When McDonald’s opened,
their opening day here surpassed any other openings in the United States.” (Schoenberg et al.,
2015). Many Appalachian residents know a “Big Mac” may not be the healthiest option but will
accept the consequences due to convenience or the marketing of the item influences them
(Schoenberg et al., 2015). This information is alarming and demonstrates the need for rural
health care and obesity education.
Obesity Risks
With obesity and associated factors costing healthcare billions annually, and coupling this
with its comorbidities and chronicity, obesity is now considered a disease by healthcare
professionals (Garvey et al., 2016). Morbidity and mortality of obesity-related conditions make
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obesity a necessary target for intervention. Clearly healthcare providers must be fully engaged in
helping patients reach a healthy weight and use all avenues for treatment (Garvey et al., 2016).
The obesity epidemic raises the need for preventive care. Obesity alone is a major risk
factor in cardiovascular, orthopedic, and metabolic disorders (Emmett & Chandra, 2015).
Weight-related complications include: type 2 diabetes, dyslipidemia, hypertension,
cardiovascular disease, nonalcoholic fatty liver disease, polycystic ovary syndrome, female
infertility, male hypogonadism, obstructive sleep apnea, asthma/reactive airway disease,
osteoarthritis, urinary stress incontinence, gastroesophageal reflux disease, and depression
(Garvey et al., 2016). Each of these conditions can be medically managed. However, with
clinically significant weight reduction, each of these comorbidities could be remedied without
medication (Garvey et al., 2016).
Bias
Obesity is a major and growing problem, but how do you convince society of the need for
change? Emmett and Chandra (2015) conducted a study examining people’s perception of how
great a problem obesity is in the U.S.; a total of 692 Americans replied to surveys. The majority
(94.4%) were aware that obesity is a major and growing problem (Emmett & Chandra, 2015).
This study found that people correlated obesity with diet (p. 96). Making people aware of the
consequences and causes of obesity is the first step in addressing this epidemic.
An unfortunate consequence many obese adults face is that of weight stigmatization
(Puhl, Quinn, Weisz, & Suh, 2017). Weight stigmatization, or negative societal devaluation of
people based of their excess body weight, is a form of prejudice (Puhl et al., 2017). Recent
studies show a relationship between obesity and psychological disorders (Collins, Meng, & Eng,
2016). Numerous studies report obese individuals claiming lower quality of life, decreased life
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satisfaction, anxiety, and higher incidence of depression (Collins et al., 2016; Lin et al., 2013).
Remarkably, the correlation between obesity and psychological disorders appears bidirectional;
psychological disorders may develop obesity and obese may develop psychological disorders
(Collins et al., 2016).
Vast instances of weight derogatory comments, verbal aggression, and cyber-bullying
occur daily on social media (Brun, McCarthy, McKenzie, & McGloin, 2014; Chou, Presin, &
Kunath, 2014). Meta-analyses show weight bias has negative impacts on job related outcomes
(hiring, salary, promotion status) (Roehling, Pichler, & Bruce, 2013; Vanhove & Gordon, 2014).
Evidence validates the correlation between weight stigmatization, adverse health behaviors, and
outcomes leading to weight gain such as increased risk of depression, stress, binge eating, or
reduced physical activity (Puhl et al., 2017). Currently, in the United States, obese individuals
have little to no legal protection against weight-based discrimination (Pearl, 2018). There needs
to be strategies to decrease weight bias and discrimination in the workplace, schools, and media
(Pearl, 2018).
Constant media attention about obesity-related topics continue to invade broadcasting.
The healthcare community has been found to harbor negative views about those who are
overweight or obese (Puhl, 2017). Fortunately, there does seem to be some movement by
primary care providers (PCPs) in addressing obesity. According to a study by Mehta et al.
(2012), PCPs were 2.38 times more likely to provide obesity management compared to
specialists (i.e. Gastroenterologists, Endocrinologists, Gynecologists). Further, patients who had
preventive visits and/or chronic visits were more likely to receive obesity management over
patients who only had acute visits (Mehta et al., 2012). Mehta et al. (2102) reports that more
time spent with a PCP, the number of comorbid conditions, and a BMI ≥40 significantly
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increased the likelihood of receiving obesity management. Elderly or those who smoke were
less likely to receive obesity treatment (Mehta et al., 2012). Other studies report health care
professionals as having less respect for obese patients believing they are unmotivated, lazy, and
unlikely to be compliant with treatment recommendations (Phelan et al., 2015; Puhl, Phelan,
Nadglowski, & Kyle, 2016).
Stakeholders
There are a number of stakeholders seeking to address the obesity epidemic. In 2013,
governmental agencies on the federal, state, and local level began to institute changes that would
address the growing problem of obesity. School food programs, propositioning initiatives to tax
or ban certain foods and beverages, and proposed changes in nutrition labeling have been
directed at improving American’s nutrition (Slavin, 2015). These address primary prevention,
which is easier than addressing obesity.
Countless health care organizations have developed programs of research focused on new
technology (bariatric surgery), medications, and policy advancements for decreasing obesity.
The American Association of Clinical Endocrinologists (AACE) Board of Directors and
American College of Endocrinology (ACE) Board of Trustees published standardized clinical
practice guidelines (CPGs). Each have provided recommendations for comprehensive medical
care of patients with obesity based on a diligent review of the clinical evidence (Garvey et al.,
2016).
Current Practice Guidelines & Theory
AACE/ACE Guidelines
The CPGs for comprehensive medical care of patients with obesity include evidence for
definitions, goals, and methods for phases of prevention in chronic disease. The CPGs include
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an executive summary of 123 clinical practice recommendations which cover the spectrum of
obesity management (Garvey et al., 2016). The core recommendations for medical care of
patients with obesity include three phases of chronic disease prevention and treatment (Garvey et
al., 2016). These three phases (primary, secondary, and tertiary interventions) should be the
basis of the modality and intensity of obesity interventions (Garvey et al., 2016).
Three phases. Phases of prevention include primary, secondary, and tertiary. Primary
prevention discusses ways to prevent the progress of overweight and obesity. Secondary
prevention considers ways to prevent further weight gain and weight-related complications in
patients who are overweight or obese. Tertiary prevention examines ideas of treatment with
weight-loss therapy to decrease weight-related complications and prevent advancement of
disease (Garvey et al., 2016, see table 2).
Table 2.
Three phases of Prevention in Obesity as a Chronic Disease
General Practices in Chronic Disease in Obesity
Phase of Intervention

Definition and Goals

Methods of Prevention

Primary Prevention

o

o

Eliminateariskafactors

o

Educateatheapublic

o

Promote healthy eating and regular
physicalaactivity

o

ScreenausingaBodyaMassaIndex
(BMI) annually

o

Diagnose using BMI and evaluation
for complications

o

Treatawithalifestyle/behavioral
interventionawith/withoutaweightlossamedications

Secondary Prevention

o

Preventatheadevelopmentaof
overweight and obesity

Prevent future weight gain and the
developmentaofaweight-related
complicationsainapatientsawith
overweight or obesity
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Tertiary Prevention

o

Treat with weight loss therapy to
eliminateaweight-related
complications

o

Treatawithalifestyle/behavioral
interventionsaplusaweight-loss
medications

o

Prevent disease progression

o

Considerabariatricasurgery

Note: data from American Association of Clinical Endocrinologists and American College of Endocrinology clinical
practice guidelines for comprehensive medical care of patients with obesity- Executive Summary, by Garvey et al.
Retrieved from doi: 10.4158/EP161365.G (2016).

BMI/Waist Circumference. According to Garvey et al. and the AACE/ACE CPGs,
body mass index (BMI) is the best anthropomorphic criteria for confirming an excess in
adiposity (2016). Diagnosing individuals as being overweight or obese in the clinical setting is
based on BMI. BMI is constructed using the formula weight in kilograms divided by height in
meters squared (BMI= wt in kg/ht in m2). Clinical evaluation must be considered when using
BMI, taking in to account the age, gender, ethnicity, fluid status, and muscularity (Garvey et al.,
2016). Individuals are considered overweight with a BMI of 25-29.9 kg/m2 and obese with a
BMI of ≥ 30 kg/m2 (Garvey et al., 2016).
Other methods of measure for adiposity such as air/water displacement or dual-energy xray absorptiometry may be used if BMI and physical exam require further evaluation; cost,
availability, and lack of validity do not support these methods (Garvey et al., 2016). In addition
to BMI, adiposity-related disease risk should be evaluated for every patient based on waist
circumference (Garvey et al., 2016). In the United States, indication of increased risk of disease
are waist circumference ≥ 40 inches (≥ 102 cm) in men and ≥ 35 inches (≥ 88 cm) in women
(Garvey et al., 2016, see table 3).
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Table 3.
Classification of Overweight and Obesity by BMI and Waist Circumference
Classification of Overweight and Obesity by BMI and Waist Circumference
per AACE/ACE CPG
Classification

BMI
BMI (kg/m2)

Waist
Comorbidity
Risk

Waist Circumference and Comorbidity Risk
Men ≤40 in (102 cm)
Women ≤35 in (88 cm)

Men >40 in (102 cm)
Women >35 in (88 cm)

Underweight

<18.5

Low

Normal weight

18.5-24.9

Average

Overweight

25-29.9

Increased

Increased

High

Obese class I

30-34.9

Moderate

High

Very High

Obese class II

35-39.9

Severe

Very High

Very High

Obese class III

≥40

Very Severe

Extremely High

Extremely High

Abbreviations: BMI= body mass index; in= inches
Note: data from American Association of Clinical Endocrinologists and American College of Endocrinology clinical
practice guidelines for comprehensive medical care of patients with obesity- Executive Summary, by Garvey et al.
Retrieved from doi: 10.4158/EP161365.G (2016).

Weight Related Complications & Therapeutic Benefits of Weight Loss. After initial
evaluation, and identification of weight-associated comorbidities there should be ongoing follow
up to monitor for changes in adiposity and complications (Garvey et al., 2016). In Table 4, the
effect of weight loss on known comorbidities is outlined (see Table 4). Weight loss can be an
effective treatment of weight-related conditions with significant changes seen with just a 5%
weight loss (Garvey et al., 2016).
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Table 4.
Treatment Goals Based on Diagnosis in the Medical Management of Patients with Obesity
Treatment Goals Based on Diagnosis in the Medical Management
of Patients with Obesity
Classification

Anthropometric
Component

Overweight or
Obesity

BMI ≥25 kg/m2

Tertiary Prevention
Clinical Component

Weight Loss
Goal (%)

Clinical Goals

Metabolic syndrome

10%

Prevention of T2DM

Prediabetes
T2DM

10%
5% to ≥ 15%

Prevention of T2DM
o Reduction in A1C
o Reduction in number
and/or doses of glucose
lowering medications
o Diabetes remission
especially when diabetes
duration is short

Dyslipidemia

5% to ≥ 15%

o Lower triglycerides
o Raise HDL-c
o Lower non-HDL-c

Hypertension

5% to ≥ 15%

o Lower systolic and
diastolic BP
o Reductions in number
and/or doses of
antihypertensive
medications

Steatosis

5% or more

Reduction in
intrahepatocellular lipid

Steatohepatitis

10% to 40%

Reduction in
inflammation and fibrosis

Polycystic ovary syndrome

5% to 15% or more

o Ovulation
o Regularization of
menses
o Reduced hirsutism
o Enhanced insulin
sensitivity
o Reduced serum
androgen levels

Female infertility

10% or more

o Ovulation
o Pregnancy and live
birth

5% to 10% or more

Increase serum
testosterone

7% to 11% or more

o Improved
symptomatology
o Decreased apneahypopnea index

Nonalcoholic
fatty liver
disease (NASH)

Male hypogonadism

Obstructive sleep apnea
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Asthma/reactive airway disease

Osteoarthritis

7% to 8% or more

o ≥10%
o 5% to 10% or
more when
coupled with
exercise

o Improvement in
forced expiratory
volume at 1 second
o Improved
symptomatology

o Improvement in
symptomatology
o Increased function

Urinary Stress Incontinence

5% to 10% or more

Reduced frequency of
incontinence

Gastroesophageal reflux disease

10% or more

Reduced symptom
frequency and severity

Depression

Uncertain

o Reduction in
depression
symptomatology
o Improvement in
depression scores

Abbreviations: A1C= hemoglobin A1C; BMI= body mass index; BP= blood pressure; HDL-c= high-density lipoprotein cholesterol; T2DM=
type 2 diabetes mellitus.

Note: data from American Association of Clinical Endocrinologists and American College of Endocrinology clinical
practice guidelines for comprehensive medical care of patients with obesity- Executive Summary, by Garvey et al.
Retrieved from doi: 10.4158/EP161365.G (2016).

Lifestyle & Behavioral Therapy and Plan. Along with evaluation, the AACE/ACE
CPGs recommend a structured lifestyle intervention program designed for weight loss (2016).
This should include healthy meal planning, physical activity, and behavioral interventions
(Garvey et al., 2016). According to Garvey et al., a reduced total energy (caloric) intake should
be the main component for interventional weight-loss. Meal plans should include a daily
reduction of 500-750 kcal. Dietary considerations can include the Mediterranean, DASH, lowcarb, low-fat, high protein, or vegetarian diets, and/or meal replacements. Expertise from a
dietician or health educator is optimal (Garvey et al., 2016). The CPGs do not recommend one
specific diet over another. Diets that fit the individual’s lifestyle and likes/dislikes are important
to take in to consideration to avoid barriers to weight loss.

14
Reduction of sedentary lifestyle with an individualized program based on goals,
preferences, and limitations should be discussed with an expert (trainer, coach,
physical/occupational therapist) when possible (Garvey et al., 2016). The AACE/ACE CPGs
recommend aerobic physical activity progressing to >150 minutes/week 3 to 5 days per week
along with resistance exercise involving major muscle groups 2 - 3 times/week (2016). Given
the current level of exercise reported by the vast majority of those who are obese, there should be
a gradual progression to the recommended time of exercise.
Educational material on behavioral modification ought to be reviewed with a health
educator, clinician, behaviorist, or clinical psychologist/psychiatrist (Garvey et al., 2016). These
materials should include helpful strategies in adhering to diet and exercise recommendations and
self-monitoring of their weight loss strategies. Patients are encouraged to set reasonable goals
and be assisted in problem solving and coping as they engage in their weight loss journey.
Support systems, such as group meetings or face-to-face sessions, along with identifying daily
lifestyle barriers must be addressed (Garvey et al., 2016).
In addition to lifestyle therapy, pharmacotherapy can be considered in those who are
overweight or obese specifically those with weight-related complications that can be improved
by weight loss (Garvey et al., 2016). It is important to note the recommended AACE/ACE CPGs
(2016) state, “pharmacotherapy for overweight and obesity should be used only as an adjunct to
lifestyle therapy and not alone” (p. 36). For optimal weight-loss, clinicians need to consider
patient specific medications considering efficacy, side effects, contraindications, medical history,
and presence of weight-related complications (Garvey et al., 2016).
For individuals that have failed or have contraindications for pharmacotherapy, bariatric
surgery may be an effective obesity treatment. Patients with BMI ≥40 kg/m2 without coexisting
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medical problems, patients with BMI ≥35 kg/m2 with one or more severe obesity-related
complication (T2DM, hypertension, NASH, etc...), or patients with BMI of 30 to 34.9 kg/m2 with
diabetes or metabolic syndrome may be considered for a bariatric surgery procedure (Garvey et
al., 2016). Surgery is not without risks nor without significant lifestyle changes.
Despite knowledge of diet and exercise, pharmacotherapy, and the advent of new
technology (wearable fitness devices and wellness apps), obesity rates continue to escalate.
Short-term treatment (3-6 months) with weight-loss medications has not been proven effective in
producing long-term health benefits, so maintenance of weight loss is imperative but remains
challenging (Garvey et al., 2016). Even weight loss surgery has not been met with a complete
reversal of obesity. In those who have had surgery, not following the recommended diet can lead
to weight gain not weight loss. Without adequate motivation, solutions will be hard to
implement (Emmett & Chandra, 2015).
Theory
The motivation to lose and maintain weight loss requires dedicated strategies. A
psychological theory of motivation, the Self-Determination Theory (SDT), along with coaching
techniques can help overweight and obese individuals as they adopt healthy lifestyle habits and
increase physical activity (Clarke, 2017). The main idea of SDT centers around three basic
needs that promote motivation: autonomy, competence, and relatedness (Clarke, 2017, see table
5).
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Table 5.
Self-Determination Theory, basic needs
Basic need that
promotes
motivation

Definition

Definition related to
weight-loss

Example

Autonomy

-When one acts on
his/her own terms

-Exploring one’s own
perspectives on
behaviors related to
physical activity or
weight loss
interventions

-If an individual
physically cannot run
or does not like to
run, it is important
that this is
acknowledged and
other alternatives for
activities are explored

Competence

-When one feels
confident they have
the ability and
resources to achieve a
goal

-Optimism,
positivity, and
providing positive
feedback suggest
one’s ability for
successfully adopting
and performing new
behaviors

-A lapse in behavior,
such as failure to
exercise, should be
considered a
temporary setback on
the road to success

Relatedness

-Having substantial
and supportive
relationships (family,
friends, healthcare
providers,
coaches/trainers)

-Occurs with a
support system,
meeting new people
and groups, and
networking

-A support group
such as weightwatchers that helps
attain goals.

Note: data adapted from multiple sources (Clarke, 2017; Patrick & Williams, 2012).
Through autonomy (supporting and recognizing an individual’s lifestyle) this gives the
individual an opportunity to express perspectives and concerns thus strengthening commitment
and accountability for desired behavior change (Patrick & Williams, 2012). By using skills such
as problem solving and contingency planning, competence is enhanced, and the individual can
effectively learn to cope with challenges, avoid setbacks, and continue his/her ongoing success
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(Nag & Durand, 2016; Patrick & Williams, 2012). Relatedness is reaching a goal with the help
of a support system. This is important in the sustainability of behavior change.
According to a systematic literature review completed by Teixeira et al. (2012), the most
important skill correlated with successful weight loss outcomes was the use of self-regulation.
Self-regulation includes monitoring weight and food choices, goal setting and planning
(Teixeira, Carraca, Markland, Silva, & Ryan, 2012). Based on the CPGs, after education,
motivation, and attempting lifestyle/behavior change, pharmacologic options should be
incorporated.
Pharmacologic Weight Management
History of Weight Loss Medications
Medications for weight management has been associated with significant negative effects
and perhaps it is this history that impedes providers from exploring the newer drugs. The first
weight loss medications were introduced in the 1900s. These anti-obesity medications involved
increasing basal metabolic rates (BMR) (Adan, 2013). Thyroid hormones and Tenuate
(dinitrophenol) were the first prescription drugs for weight loss, but the increase in BMR caused
overheating and death (Adan, 2013).
Later, amphetamines, introduced in the 1930s, looked promising for weight loss but were
found to be addictive and produced cardiovascular side effects (Adan, 2013). However, in 1992,
fenfluramine was combined with phentermine (Fen-phen) and gained international attention with
efficacy of up to 10% bodyweight (Adan, 2013). Unfortunately, this medication combo was
discontinued after notable causes of pulmonary hypertension (Adan, 2013). In 1997, the FDA
approved sibutramine, but due to cardiovascular changes leading to cardiovascular events (stroke
and myocardial infarction) the medication was discontinued (Adan, 2013).
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Subsequently, in 1997 Orlistat was introduced; however, side effects such as fecal
incontinence and oily stools led to poor compliance (Adan, 2013). Excitingly, in 2012, Qsymia
(phentermine plus topiramate) and Contrave (bupropion plus naltrexone), both polytherapies, and
Belviq (lorcaserin) were added to the FDA approval list and show great promise for obesity
treatment (Adan, 2013). Saxenda (the newest medication) received approval in 2014 and has
supportive long-term data for meaningful weight loss, shows great efficacy, but is cost
constraining (Velazquez & Apovian, 2018).
Current Prescribing Practices
Nationally, obesity is a chronic disease that affects over 78 million adults, yet only 2% of
all eligible obese adults receive pharmacotherapy from a provider (Mehta et al., 2012; Velazquez
& Apovian, 2018). According to a Medscape survey of 1282 healthcare providers, only 58%
prescribed weight loss medications to those who were overweight/obese (Garvey & Wiebe,
2018). Currently in the U.S. there are eight Food and Drug Administration (FDA)-approved
drugs used to help aid in weight loss (Velazquez & Apovian, 2018).
Each medication impacts the body in different ways. Pharmacologic interventions
include those that act centrally as noradrenergic agents, medications that interfere with fat
absorption, and an analog of human glucagon-like peptide-1 (GLP-1) which suppresses appetite.
Three of the most common medications within these categories, Adipex, Contrave, and Saxenda,
were evaluated in their efficacy for weight loss.
In 1959, Adipex (phentermine), another amphetamine, was introduced (Adan, 2013).
Adipex remains the most commonly prescribed and well researched today due to affordability
and limited side effects (Adan, 2013; Velazquez & Apovian, 2018). Adipex (phentermine),
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Tenuate (diethylpropion), Bontril (phendimetrazine), and Didrex (benzphetamine), act as
appetite suppressants by affecting the central nervous system (Yanovski & Yanovski, 2014).
Adipex (phentermine) is indicated for those with a BMI of ≥30 kg/m2 or BMI ≥27 kg/m2
with comorbidities (Phentermine (Rx), 2016). In the United States, an estimated 25.3 million
prescriptions were dispensed between 2008-2011 (Velazquez & Apovian, 2018; Yanovski &
Yanovski, 2014). This very affordable medication has been proven to result in clinically
significant weight loss in a short time (12 weeks) with adjunctive lifestyle modification
(Velazquez & Apovian, 2018).
Between 2008-2011, according to the National Institute of Health public access, patients
using 15-30 mg/d Adipex had a mean total weight loss of 6.3 kg based on a meta-analysis of six
studies over 2 to 24 weeks (Yanovski & Yanovski, 2014). Combination therapy with low doses
of Adipex have been approved for long-term obesity management. While Adipex alone has been
prescribed long term without evidence of serious side effects and low levels of potential
addiction, long-term studies are lacking on monotherapy effects and cardiovascular risk; hence,
more long-term studies are needed (Yanovski & Yanovski, 2014).
Orlistat, a gastrointestinal lipase inhibitor, defers fat absorption by blocking some of the
fat you eat (Yanovski & Yanovski, 2014). The side effect profile is unpalatable which has
decreased its favorability among patients. A version of Orlistat was reformulated to be over the
counter (Alli) which unfortunately did not improve its acceptability (Yanovski & Yanovski,
2014).
Belviq (Lorcaserin), a serotonin receptor activator, works as an appetite suppressant by
affecting chemical signals in the brain that control appetite (Yanovski & Yanovski, 2014). Two
combination medications, Qsymia (phentermine plus topiramate-ER) and Contrave (naltrexone
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plus bupropion-SR), work together to suppress appetite (Yanovski & Yanovski, 2014).
Regarding Qsymia, phentermine is a noradrenergic agonist, and topiramate ER acts on GABA
receptors leading to appetite suppression (Velazquez & Apovian, 2018). For Contrave, the
mechanism of action for buproprion SR is the inhibition of dopamine and norepinephrine
reuptake; naltrexone acts to antagonize the feedback loop that limits buproprion’s anorexic
effects, thus the drugs work together to produce appetite suppression (Velazquez & Apovian,
2018). Interestingly, Contrave is a combination of naltrexone and bupropion; naltrexone is
approved to treat alcohol and opioid dependence and bupropion is approved to treat depression
and seasonal affective disorder and as an aid to smoking cessation treatment (FDA, 2014).
The FDA approved Contrave for long-term use in adults with a BMI of ≥30 kg/m2 or
adults with a BMI ≥27 kg/m2 who have at least one weight-related condition such as high blood
pressure, type 2 diabetes, or high cholesterol (FDA, 2014). The effectiveness of Contrave was
evaluated in multiple clinical trials. In one trial, 42% of patients treated with Contrave lost at
least 5% of their body weight compared with 17% of patients treated with placebo (FDA, 2014).
Approved in 2014 by the FDA, Saxenda (liraglutide), a GLP-1 receptor agonist, is the
only long-acting daily injectable therapy approved for medical weight loss (Curry, 2017; Isaacs
et al., 2016). Saxenda (liraglutide) is the newest weight loss medication on the market and is an
analog of human glucagon-like peptide-1 (GLP-1) (Velazquez & Apovian, 2018). Saxenda
mimics the endogenous GLP-1 hormone (Velazquez & Apovian, 2018). This hormone is
released from the small intestines producing appetite suppression and increases the release of
insulin from the pancreas when glucose is present (Velazquez & Apovian, 2018).
Interestingly, recent research has shown medications used for glycemic control in those
with type 2 diabetes (T2DM), known as GLP-1 receptor agonists, have produced weight loss
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effects in patients with or without diabetes (Isaacs, Prasad-Reddy, & Srivastava, 2016). Saxenda
has proven to be effective in moderate weight loss. It has been shown to decrease systolic blood
pressure and reduce lipid parameters with minimal side effects including gastrointestinal
symptoms such as nausea, vomiting, and diarrhea (Abramowicz et al., 2016; Curry, 2017; Scott,
2015).
A one-year study showed an average of 5.6% decrease in total body weight in those
treated with Saxenda (Garvey et al., 2016). One well-designed 56-week phase III trial showed
Saxenda was associated with significant (p< .0001) waist circumference and BMI reductions
from baseline to 56 weeks (Bode et al., 2014). Waist circumference was reduced by 4.7 cm in
the Saxenda group compared to 1.2 cm in the placebo group (Bode et al., 2014). Unfortunately,
this is the most expensive antiobesity medication on the market at approximately $1100 per
month (Curry, 2017).
Cost of Medication
The Affordable Care Act (ACA) covers obesity screenings and counseling (Wilson, Kyle,
Nadglowski, & Stanford, 2017). However, obesity treatments, such as medical weight
management programs and medications, are not considered essential benefits and many states
provide minimal or no coverage for these treatments (Wilson et al., 2017; Yang & Pomeranz,
2015). One study, among 136 marketplace health insurance plans, showed merely 11% had
some coverage for drugs (such as Adipex, Contrave, and Saxenda) in only 9 states (Gomez &
Stanford, 2018). Medicare policy strictly excludes drug therapy for obesity treatment, and only
seven states have Medicaid drug coverage for antiobesity medications (Gomez & Stanford,
2018). Ironically, federal government employees (consisting of roughly 2.7 million
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beneficiaries) have health benefit plans that are not allowed to exclude coverage of antiobesity
medications (Gomez & Stanford, 2018).
Another study found that obese patients stay on medication longer, see his/her PCP more
often, and lose more weight with adequate medication reimbursement (Baum et al., 2015). With
the proven clinical effects of pharmacologic obesity management and reducing weight-related
complications, this information indicates a need for broader coverage of pharmacotherapy
(Gomez & Stanford, 2018). Each FDA approved medication included in this study is listed
below along with the mechanism of action, side effects, and overall cost (see table 6). Clearly,
one can see that Adipex is the most cost effective.
Table 6.
Medication Overview
Drug/dose

Mechanism
of action

Side effects

Contraindicat
ions

Adipex
(phentermine)
15-37.5 mg
oral

Nonadrenalin
releaser,
appetite
suppressant

Insomnia,
elevation in
heart rate, dry
mouth, taste
alterations,
dizziness,
tremors,
headache,
diarrhea,
constipation,
vomiting,
gastrointestina
l distress,
anxiety, and
restlessness

Not for
patients with
advanced
cardiovascular
disease,
moderate to
severe
hypertension,
hyperthyroidis
m, glaucoma,
and agitate
states

Cost/mon
th (some
not
covered
by
insurance
plans)
$6-45

Efficacy
in % of
body
weight

∆
waist
circum
ferenc
e

-5-10%

-3-4.5
inches
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Contrave
(bupropion
with
naltrexone)
8 mg/90 mg
oral

Noradrenalin
/dopamine
reuptake
inhibitor and
opioid
receptor
antagonist

Liraglutide
(Saxenda) 3mg
SQ

GLP-1
receptor
agonist at
satiety center
of brain,
resulting in
slowed
gastric
emptying

Cardiovascula
r side effects
(monitor for
increase heart
rate and blood
pressure),
nausea,
vomiting,
diarrhea,
headache,
dizziness,
insomnia

Not for
$90-255
patients with
uncontrolled
hypertension,
chronic opioid
use, seizure
disorder,
anorexia or
bulimia, during
withdrawal
from alcohol,
barbituates,
benzodiazepine
s, and
antiepileptic
drugs
Nausea,
Not for
$1,150
vomiting,
patients with
gastrointestina personal or
l symptoms,
family history
possible
of medullary
hypoglycemia thyroid
, abdominal
carcinoma or
pain,
Multiple
headache,
Endocrine
fatigue,
Neoplasia
increased
syndrome type
lipase
2. Should not
be used with
Potential
insulin or other
serious
GLP-1
toxicities:
agonists.
pancreatitis,
medullary
thyroid
carcinoma

-5-10%

-2-4
inches

Loss of
3.6-5
kgs

4.7 cm

**All antiobesity drugs are contraindicated in pregnancy.
Note: Data adapted from multiple sources, (Adan, 2013; Fujioka & Braverman-Panza, 2016;
Gadde et al., 2018; Goodrx, 2017; Isaacs et al., 2016; Scott, 2015; Yanovski & Yanovski, 2014).

Although lifestyle/behavioral interventions are primary in management, most overweight
or obese individuals require adjunctive pharmacotherapy to achieve clinically significant weight
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loss (≥ 5% bodyweight reduction) (Scott, 2015). The initial weight loss goal with behavioral
changes and pharmacotherapy is 5% or more of total body weight (Velazquez & Apovian, 2018).
This weight loss has proven sufficient in reduction of health risks such as hypertension, T2DM,
and hyperlipidemia (Velazquez & Apovian, 2018). According to Velazquez and Apovian
(2018), “the objective for using pharmacotherapy to manage obesity is to amplify patient
adherence to lifestyle changes and to overcome the biological adaptations that occur with weight
loss” (p. 107). The quality improvement project proposed in this paper will evaluate the impact
of medications Adipex, Adipex plus Contrave, and Adipex plus Saxenda and their effectiveness
on BMI, weight loss, and waist circumference.
Purpose
Project Aims
AIM 1: To determine the effectiveness of Adipex on BMI, weight loss, and waist circumference
in patients at a rural weight loss clinic.
1. Was BMI, weight, and waist circumference effected in Adipex patients?
2. Did Adipex have barriers (side effects) that prevented medication adherence?
AIM 2: To determine the effectiveness of Adipex plus Contrave on BMI, weight loss, and waist
circumference in patients at a rural weight loss clinic.
1. Was BMI, weight, and waist circumference effected in Adipex plus Contrave patients?
2. Did Adipex plus Contrave have barriers (side effects) that prevented medication
adherence?
AIM 3: To determine the effectiveness of Adipex plus Saxenda on BMI, weight loss, and waist
circumference in patients at a rural weight loss clinic.
1. Was BMI, weight, and waist circumference effected in Adipex plus Saxenda patients?
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2. Did Adipex plus Saxenda have barriers (side effects) that prevented medication
adherence?
Objectives:
A. Examine a group of 30-100 patients at a rural weight loss clinic taking weight loss
medications from September 2014- September 2017.
a. Each patient was followed for an initial visit, 2-month visit, 3-month visit, and 6month visit.
i. Visit 1- Gather baseline data and medication were prescribed
1. Initial measurements (BMI, weight, waist circumference)
2. Demographic information, co-morbidities, smoking and alcohol
use
3. Diet and exercise plan
ii. 2-month visit
1. Measurements (BMI, weight, waist circumference)
2. Counseling on diet and exercise adherence
3. Side effect discussion
iii. 3-month visit
1. Measurements (BMI, weight, waist circumference)
2. Counseling on diet and exercise adherence
3. Side effect discussion
iv. 6-month visit, has patient experienced decreased BMI, weight loss, or
waist circumference?
1. Measurements (BMI, weight, waist circumference)
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2. Counseling on diet and exercise adherence
3. Side effect discussion
B. Was there any change in metabolic profile between visits?
a. Changes in measurements (BMI, weight, waist circumference)
Methods
This project was a single-center retrospective study of the comparison of three different
groups taking Adipex, Adipex plus Contrave, and Apidex plus Saxenda and the effect on weight
loss, BMI, and waist circumference. This project also compared the medications on
comorbidities and demographics. The sample consisted of 84 patients from a rural weight loss
clinic evaluated from September 2014 to September 2017.
Setting
The rural weight loss clinic is a group that specializes in weight loss evaluation,
treatment, and management. The clinic is owned by a Family Nurse Practitioner who is the
primary provider in the clinic. Improving the overall health of individuals that struggle with
being overweight and obese is accomplished within this clinic by educating, assessing,
encouraging, motivating, and providing supportive therapy. The rural weight loss clinic provides
a medically-supervised weight loss program for people who would like to improve their health
by losing weight. The nurse practitioner uses the dual approach of lifestyle modification and
anti-obesity medications.
The clinic has been open since 2010. The provider has not completed a thorough
assessment of their weight loss outcomes and has requested a chart review. In this setting, the
effectiveness of weight loss medications in the treatment of obesity has not been documented.
This project was focused on reviewing patient data who have been prescribed Adipex, Adipex
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plus Contrave, and Adipex plus Saxenda, and compared the effectiveness of each. Evaluation of
effectiveness was based on Body mass index kg/m2 (BMI), weight in pounds (lbs), and waist
circumference (inches).
Sample
For this project, three different groups were evaluated. All selected participants were
rural weight loss clinic patients. The review was conducted between September 2014September 2017. The groups consisted of 34 patients that have taken Adipex, 30 patients that
have taken Adipex plus Contrave, and 20 patients that have taken Adipex plus Saxenda to lose
weight.
Inclusion Criteria. Rural weight loss clinic patients only with a BMI of ≥ 27 kg/m2
(overweight) with comorbidities present or a BMI of ≥ 30 kg/m2 (obese) with or without
comorbidities present (such as hypertension, dyslipidemia, type 2 diabetes). All patients were
over the age of 18 and prescribed a weight loss medication. Adherence to a diet and exercise
regimen was required. The regimen was not prescriptive and could include participation in
group weight loss programs (i.e. Jenny Craig or Weight Watchers).
Exclusion Criteria. Patients who missed a scheduled monthly appointment or patients
who had to change medication during course of treatment.
Measurements
The following measures were extracted from the paper patient documented medical records
to provide an analysis for objectives (see table 7).
1. Body Mass Index kg/m2 (BMI), weight (lbs), and waist circumference (inches): BMI,
weight in pounds, and waist circumference in inches before and after treatment was
gathered to determine weight loss therapy effectiveness.
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2. Medication reconciliation document: The medication reconciliation document was used
to determine which patients were prescribed Adipex, Adipex plus Contrave, and Adipex
plus Saxenda.
3. Metabolic data: An initial assessment was conducted for each patient to identify vital
signs and co-morbidities.
4. Demographic data: Demographic data included gender (male vs. female), age (in years),
ethnicity, and lifestyle habits (diet, exercise, smoking, ETOH).

Table 7.
Study Measures
Outcome

Measures

Level of Measure

Time of Measure

Data
Collection

Demographic
Gender

Male vs female

Nominal

Medical records

White, black,
Hispanic,
Indian, native
American,
middle eastern,
mixed race,
Asian, other
Age in years

Nominal

Frequencies, chisquare
Frequencies, chisquare

Interval/Ratio

Frequencies, chisquare

Medical records

Nominal

Frequencies, chisquare

Medical records

Interval/Ratio

Means (SD), t-test

Medical records

Nominal

Frequencies, chisquare

Medical records

Ethnicity

Age

Program Information
Medical
Names of
Reconciliation medications
document
prescribed to
patient
Vital signs
Blood Pressure(BP, HR)
mmHg
Heart ratebeats/min
Co-morbidities Patient
documented
history

Medical records
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Lifestyle
habits (diet,
exercise,
smoking,
ETOH, drug
use)
BMI

Patient
documented
history

Nominal

Frequencies, chisquare

Medical records

kg/m2

Interval/Ratio

Medical records

Weight
Waist
Circumference
Side effects

Pounds (lbs)
Inches

Interval/Ration
Interval/Ration

Means (SD), oneway ANOVA
Means (SD), t-test
Means (SD), t-test

Patient records

Nominal

Frequencies, chisquare

Medical records

Medical records
Medical records

Data Collection
Approvals from the University of Kentucky Institutional Review Board (IRB) were
obtained prior to data collection. This project was based on a retrospective chart review. Data
collection was completed at the rural weight loss clinic. The clinic used paper documentation
and each patient file was selected based on inclusion and exclusion parameters. Data collected
was based on the table above including gender, ethnicity, age, medications, vital signs, comorbidities, lifestyle habits, BMI, weight, waist circumference, and side effects. After data was
collected from patient records, using no patient identifiers, data was transferred to an excel
spreadsheet.
Data Analysis
Descriptive statistics such as mean and standard deviation or frequency distributions were
used to summarize demographic data, medications, vitals, co-morbidities, lifestyle habits, and
side effects. The chi-squared test of association (or Fisher’s exact test, as appropriate) or the
two-sampled t-test was used to test for group differences in demographic characteristics. Oneway ANOVA tests were used to test for group differences in change in BMI, weight, and waist
circumference (from baseline to each follow up appointment). A post-hoc analysis directed any

30
significant findings for ANOVA to test which group means differed. All data analysis was
conducted using SPSS version 24 with an alpha level of .05.
Results
Sample Characteristics
A total of 250 patient charts were reviewed and 84 were selected based on the inclusion
criteria for the retrospective analysis. Of these 84 selected, 34 patients had taken Adipex, 30 had
taken Adipex + Contrave, and 20 had taken Adipex + Saxenda. Each patient had taken
medication over a 6-month period with visits at baseline, 2-months, 3-months, and 6-months.
The baseline characteristics of these patients were individually assessed. The average
age of participants was 45 years of age (range, 19-67 years of age, see table 1); 87% of
participants were female. The overall analysis consisted of 99% Caucasian participants and 1%
African American participants. The mean BMI of patients at baseline was 36 kg/m2 (range, 2554 kg/m2), average weight at baseline was 218 lbs (range, 144-358 lbs), and average waist
circumference at baseline was 40.6 inches (range, 30-60 inches). There were no differences in
baseline demographics or baseline physical characteristics between the three groups which
demonstrated an even starting point.
Overall comorbidities were assessed with majority consisting of hypertension (37%),
prediabetes or diabetes (20%), and GERD (10%). Seventeen percent (17%) reported a family
history of heart disease, 7% family history of diabetes, and 4% family history of cancer. Overall
lifestyle habits examined alcohol use and smoking with average of 15% of patients consuming
alcohol socially and 5% current smokers.
Compliance of a diet and exercise regimen was assessed for each group at each visit.
Those taking Adipex had 12% (n=4) noncompliance with a diet and exercise regimen; only half
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of those noncompliant still lost weight. Adipex + Contrave users were found to have a 23%
(n=7) noncompliance rate with diet and exercise; of those, 86% (n=6) still experienced weight
loss. Patients taking Adipex + Saxenda had a 15% (n=3) noncompliance rate with diet and
exercise; all still experienced weight loss.
Side effects for each group were evaluated. Twenty nine percent (n=10) of Adipex users
reported side effects consisting of GERD, edema, headaches, fatigue, hair loss, constipation, or
back pain. Of those 29%, less than one percent (n=2) claimed these undesirable side effects
made them noncompliant with medication adherence. Those noncompliant with medications
were also noncompliant with diet and exercise. None experienced positive changes in weight
loss, BMI, or waist circumference when they did not adhere to the medication or a diet and
exercise regimen.
The other groups had combined prescribed medications. The Adipex + Contrave group
reported 15% (n=5) experienced side effects such as diarrhea, constipation, and fatigue. This
group had a 10% (n=3) noncompliance with medication regimen. Side effects were not a factor
in medication adherence for this group. Those that did not take medication as prescribed still
adhered to a diet and exercise regimen and experienced a reduction in weight, BMI, and waist
circumference.
Adipex + Saxenda users reported 17% (n=5) that experienced side effects such as fatigue,
dizziness, constipation, or diarrhea. Of those with side effects, 10% (n= 2) were noncompliant
with medication adherence. These patients did not maintain a diet and exercise regimen, but still
experienced reduction in BMI, weight, and waist circumference, although minimal.
Overall, 32% of patients reported using a weight loss app on his/her smartphone, 63%
reported following a low calorie, high protein diet, and 89% reported some form of
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cardiovascular exercise at least twice a week. Overall mean baseline vital signs were 113
systolic and 74 diastolic (mmHg), 88 heart rate, 17 respiratory rate (breaths/min), 96.7º
temperature (ºFahrenheit), and 98% oxygen saturation (room air). No significant vital sign
changes or outliers were noted throughout the project.
Findings
Intragroup Data
BMI. Individual assessment of BMI for each group was evaluated using a paired t-test
(see figure 1). Adipex users experienced an average of 2.7 kg/m2 reduction in BMI (p= .000).
Adipex + Contrave patients had a mean 2.5 kg/m2 reduction in BMI (p=.000). The Adipex +
Saxenda group resulted in an average loss of 2.7 kg/m2 in BMI (p= .001). Each group had a
statistically significant reduction in BMI.

Figure 1. BMI Loss per Individual Medication
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Medications
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BMI 6-months

Note: Each group had a statistically significant BMI reduction.
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Weight. Comparing individual drugs and the effect on weight was conducted using a
paired t-test (see figure 2). Adipex users experienced an average of 16.3 pounds lost (p= .000).
Adipex + Contrave patients had a weight loss of 15 pounds (p=.000). The Adipex + Saxenda
group resulted in an average loss of 21 pounds (p= .000). Each group had a statistically
significant reduction in weight.

Figure 2. Weight Loss per Individual Medication
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Note: Each group had a statistically significant weight loss.

Waist Circumference. Individual comparison of each drug and the effect on waist
circumference was conducted using a paired t-test (see figure 3). Adipex users experienced a
mean of 3.1 inches lost (p= .000). Adipex + Contrave patients had a waist circumference loss of
3.8 inches (p=.000). The Adipex + Saxenda group resulted in an average loss of 4.8 inches (p=
.000). Each group had a statistically significant reduction in weight.
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Figure 3. Waist Circumference Loss per Individual Medication
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Note: Each group had a statistically significant loss in waist circumference.

Intergroup Comparison. A one-way ANOVA performed between the three groups for
comparison showed no statistical significance in baseline data on age, weight, BMI, and waist
circumference. Using a one-way ANOVA, the three groups were compared to note differences
in weight, BMI, and waist circumference from baseline to 2-months, baseline to 3-months, and
baseline to 6 months. No statistical difference was found in BMI (base – 2 mo, p=.506; base – 3
mo, p=.853; base – 6 mo, p=.961; see figure 4) or weight (base – 2 mo, p=.681; base – 3 mo,
p=.451; base – 6 mo, p=.314; see figure 5). The one-way ANOVA comparing the three groups
in change in waist circumference from baseline to 3 months was significant (p=.027; see figure
6). In the post hoc analysis, Adipex + Saxenda users had a significantly higher waist
circumference difference compared to Adipex (p=.01) and Adipex + Contrave users (p=.03).
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Figure 4. Average BMI Loss Comparing Groups
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Note: there were no statistical differences in BMI loss between groups.

Figure 5. Average Weight Loss Comparing Groups
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Note: there was no statistical difference in weight loss between groups.
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Figure 6. Average Waist Circumference Loss Comparing Groups
6

Inches Lost in Waist

5
4
3
2
1
0
Baseline to 2-months

Baseline to 3-months

Baseline to 6-months

Time Point
Adipex

Contrave + Adipex

Saxenda + Adipex

Note: Statistical significance was noted from baseline to 3-months in waist circumference loss.

Between the three groups, there was no statistical significance in the percentage of weight
loss. On average, all groups experienced clinically significant weight loss (>5% total weight loss
percentage). Patients taking Adipex experienced 7.2% weight loss percentage (range, -3.5 to
16%, see figure 7). Patients taking Adipex + Contrave also averaged a weight loss percentage of
7.2% (range, -7.5 to 16%). Those taking Adipex + Saxenda averaged the most weight loss
percentage of 9.1% (range, 2 to 22%).
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Figure 7. Average Weight Loss Percentage over 6 months
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Note: there was no statistical difference in weight loss percentage between groups.

Discussion
The growing emphasis placed on weight loss has spurred the opening of dedicated clinics
to assist people with their weight loss journey. Evaluating results in patients who attend such a
clinic must be viewed under the lens of self-selection. These patients elect to seek out treatment
outside of just diet and exercise. Many providers in the primary care setting only decide to initiate
weight loss medications after a patient has trialed a recommended diet and exercise plan (Garvey
& Wiebe, 2018). While patients may be trialing diet and exercise regimens, many become
discouraged by lack of fast weight loss and seek pharmacotherapy at weight loss clinics
(Heymsfield & Wadden, 2017).
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Demographics
Nationally, in 2014, those between the age of 40-59 years were more likely to be obese
(41%) thus correlating with the average age in this study of 45 years (State of Obesity, 2017).
Ethnically, this project was not diverse. According to studies, African American women report
taking pride and having a positive body image, while white women expressed self-depreciation
and depression (Chugh, Friedman, Clemow, & Ferrante, 2013). This information concurred with
the data of primarily white females for this project.
Age, gender, and race were not evaluated between groups for the effectiveness of
medications due to the small and unvaried sample size. In completing the review of literature, no
evidence was noted that there is a difference between ethnicities, gender, or age and the
effectiveness of weight loss medications. Though, socioeconomic status was not addressed in
this project, it would have offered insight to the burden of cost on taking prescription weight loss
medications. Of note, many of the patients evaluated in this project did have insurance coverage.
Whether the insurance covered the medications prescribed could not be determined.
Medications
According to literature, numerous studies have shown greater weight loss outcomes with
combination therapy as opposed to monotherapy (Velasquez & Apovian, 2018). This retrospective
analysis did not statistically support those findings. However, this could be due to the small sample
size, noncompliance, or lack of proper medication choice for the patient as everybody responds
differently.
Adipex. Per discussion with the provider of the weight loss clinic, patients often present
requesting Adipex. They have heard of its effectiveness and affordability. Adipex is the cheapest
weight loss medication available with minimal side effects (Adan, 2013). While the side effect
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profile was largest for this group (29%), side effects were not serious and did not lead to significant
medication noncompliance. For over two decades, this medication has been prescribed in the U.S.
without serious side effects and low addiction potential (Velasquez & Apovian, 2018). Findings
in this retrospective analysis support its effectiveness making this medication a feasible first line
option for weight loss management.
Adipex + Contrave. Contrave has demonstrated effectiveness when used alone. There
was no evidence to support adding Adipex to Contrave. Per comparison with other studies,
common side effects such as gastrointestinal upset correlated with the project findings (Velasquez
& Apovian, 2018). With no evidence found in this project to suggest Adipex and Contrave had
more benefits than Adipex alone, it is the addition side effect profile that must be considered when
adding another drug, although only 15% experienced minimal side effects in this project.
Adipex + Saxenda. Adipex + Saxenda demonstrated no added benefit when combined
for weight loss. Only 17% experienced minimal side effects, and those noncompliant with diet
and exercise still experienced weight loss. Findings of weight loss while using medication only
correlates with literature reviews (Velasquez & Apovian, 2018).
A Statistical significant difference in waist circumference was noted between the groups.
From baseline to 3-month data point, Adipex + Saxenda users had the greatest reduction. This
finding remains curious as there was no real difference in the amount of weight lost between
groups. One might surmise that either waist circumference was not measured properly, or body
shape could influence area of weight loss. Saxenda is a GLP-1 receptor agonist creating insulin
sensitivity and targets adiposity in the abdominal region; which could explain waist reduction
(Velazquez & Apovian, 2018). Waist circumference has not been adopted as a standard for
evaluating for obesity because of the variability in measurement (Ma et al., 2013).
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Comorbidities. The only comorbidity that was evaluated was hypertension. In this
sample, there was no evidence of hypertension. At baseline, none were hypertensive (even the
ones reporting hypertension in medical history) which could indicate they were already receiving
treatment. Given that this clinic was still using paper charts, a complete medication list was not
readily found. Laboratory values were not included or assessed to follow improvements in
hyperlipidemia, thyroid issues, diabetes, or other comorbidites.
Interestingly, in this analysis there was only 3% depression/anxiety comorbidities
reported overall. It was difficult to interpret this finding given the medication list was not
complete. Per research findings, psychological symptoms such as anxiety and depression show a
bidirectional relationship with obesity (Collins et al, 2016). Given the data, a higher percentage
of patients in this analysis were expected to report depression and anxiety as a comorbidity.
Sample size and ongoing treatment could have influenced this finding.
Medication Compliance. Medication, diet, and exercise compliance were assessed during
this retrospective project. According to the 2018 Medscape study by Garvey and Wiebe, providers
preferred the patient to focus on diet, exercise, and behavioral therapy because they were
concerned about safety and side effects of mediations. Thirty two percent of those surveyed
admitted they did not have enough knowledge about weight loss medications (Garvey & Wiebe,
2018). Results from this project determined side effects were minimal and were not a deterrent
for adherence to medication compliance. Therefore, there is a need for provider education on side
effects and safety of weight loss medications.
Activities. Diet tracking apps, cardiovascular exercise, and low calorie high protein diets
are recommended and expected at the rural weight loss clinic. Each patient is educated on these
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aids and is strongly informed that this is a part of the weight loss plan. For good outcomes, none
of these three things can be excluded.
Compliance with cardiovascular exercise at 89% was surprising as finding time and
motivation to exercise is a barrier (Heymsfeld & Wadden, 2017). Exercise compliance was
unexpected due to Kentucky’s limited rate in physical activity of 30% (Walsh et al., 2016). It is
important to note this is a self-selected group independently seeking weight loss, which indicates
readiness for change; therefore, they are more motivated to adopt these lifestyle changes.
Implications
Primary care providers have a great responsibility in obesity education and management.
Clinical Practice Guidelines provide vast information on obesity screening and management as
well as comorbidity assessments. Evaluation of BMI should be evaluated at least annually for
each patient, screening for overweight and obesity, and then treating per guideline
recommendations.
Based on the CPGs, PCPs should be addressing and treating overweight individuals as a
precursor and work towards preventing the disease of obesity. Similar to hypertension,
education and options for diet and exercise should be presented to the patient well before the
patient nears the overweight BMI window. The progression to obesity and other comorbidities
can be offset with dedicated interventions.
Any environmental characteristic that acts as barrier to healthy body weight is considered
obesogenic (Lakerveld, Mackenbach, Rutter, & Brug, 2018). Poor diet and sedentary lifestyle
are modifiable factors that are directly linked to our obesogenic environment (Lakerveld et al.,
2018). Our surrounding such as availability of food, food traditions, institutional rules (school
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food rules), and food prices effect our diet and lifestyle decisions daily (Lakerveld et al., 2018).
Ways to avoid these barriers should be addressed with patients.
The difficulties of achieving and maintaining weight loss is a significant challenge where
all barriers should be addressed (Puhl et al., 2017). Addressing barriers such as bias, access to
care, socioeconomic factors, cost, and lifestyle/behavior should be included in evaluation and
planning of overweight and obese patients. With this knowledge, we need to start looking at
novel interventions such as telemedicine. Telemedicine, health groups, and trainers should be
included in aiding weight loss if possible (Alencar et al., 2017). Mobile phone-based health
coaching and weekly video conferencing have been effective in clinically significant weight loss
(Alencar et al., 2017). Use of smartphone apps and wearable fitness devices should be
encouraged if the individual views it as necessary to aid in weight loss/management.
More importantly, PCPs need to step up and embrace actively helping their patients lose
weight. One might wonder why we need dedicated weight loss clinics where diet, exercise, and
weight loss medications are sought out. In essence, this can create silos of patient care where
coordination of care is impeded and is more costly for this patient. For example, a patient must
pay a copay every time he/she goes to the PCP and weight loss clinic. What is it that makes
PCPs not address weight loss strategies?
Weight stigmatization affects obese individuals every day and opportunities for
improvement in the workplace, schools, healthcare, and media are beginning to be discussed at a
federal level (Pearl, 2018). As providers, overcoming weight stigmatization and incorporating
the SDT as a model of practice could have positive results on weight management. Helping
individuals adopt coping strategies to deal with stigmatization and emotional distress will
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advance weight loss management and facilitate opportunities for intervention and improve social
identity (Pearl, 2018; Puhl et al., 2017).
Is it possible that weight stigmatization is what drives individuals to a weight loss clinic?
They may feel that talking to the PCP and asking for a weight loss medication is a sign of
weakness or they will be lectured on diet and exercise compliance. In one study, patients stated
they let comorbidities exacerbate to a severe degree before seeking care because they wanted to
avoid feeling shamed by their provider (Okwerekwu, 2016). All healthcare providers are
encumbered to recognize obesity as a disease and treat as aggressively as they may treat heart
disease but approach the issue without bias.
Limitations
Several limitations should be acknowledged. The generalization of the study was limited
to data collection only being from one establishment. Due to the rural nature of the clinic, the
sample size for this project was small and consisted of a significantly non-diverse population.
Statistical difference between groups could have been limited due to small sample size. Paper
documentation of patient health records increased the difficulty and time constraint of data
collection limiting the number of participants, accuracy of information input, and amount of data
collected (lab values, concurrent medications, change in comorbidities, cost per individual).
Because this study was retrospective, verification of reported results was not possible.
Compliance of diet, exercise, and medication regimen could have skewed results.
Conclusion
Rates of obesity are predicted to rise, with attention to the severely obese subgroup (BMI
>40) which is increasing rapidly (Gotthardt & Bello, 2016; Sturm & Hattori, 2013; Velazquez &
Apovian, 2018). Although not a cure all, anti-obesity pharmacotherapy serves as a part of the
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solution for the obesity epidemic in the U.S. (Gomez & Standford, 2018). It is important to note,
pharmacotherapy is an adjunctive therapy to diet and exercise and has not proven significant
weight loss without adherence to a diet and exercise plan. Discussion of weight loss medication
should be included with every overweight/obese individual that falls in to recommended
guidelines. PCPs with time constraints or lack of knowledge about medication should refer
patients to weight loss clinics but all providers have to be communicating.
Despite clinically significant weight loss achieved with newer antiobesity drugs such as
Saxenda, only a small portion of eligible patients are using them due to high cost (Gadde et al.,
2018). Quality driven healthcare initiatives along with Federal and State coverage mandates
could make way for change in the coverage of obesity medications (Gomez & Stanford, 2018).
In policy, providers are the patient advocate; as providers, staying informed and engaged in
health care policy changes is imperative for change.
It took 50 years to publicize the link between tobacco use and lung cancer (Malhotra,
2016). Big Tobacco companies fought regulation, but through taxation and guidelines in
advertising, the government substantially declined tobacco consumption over the past three
decades (Malhotra, 2016). This was the single most important factor in decreasing
cardiovascular mortality during this period. Obesity is the new tobacco and will take a concerted
effort to reverse the upward trend.
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